Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

Recent & Breaking News (TSX:TH)

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights

GlobeNewswire September 5, 2023

Theratechnologies enrolling patients for trial across U.S. oncology sites

Jocelyn Aspa August 30, 2023

Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide

GlobeNewswire August 30, 2023

Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite

PR Newswire August 21, 2023

Theratechnologies Completes 1-for-4 Reverse Stock Split

GlobeNewswire July 31, 2023

Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management

GlobeNewswire July 28, 2023

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn

GlobeNewswire July 21, 2023

Theratechnologies Announces 1-for-4 Reverse Stock Split

GlobeNewswire July 20, 2023

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire July 12, 2023

Canadian Investment Regulatory Organization Trading Halt - TH.DB.U

Canada NewsWire June 30, 2023

Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update

GlobeNewswire June 29, 2023

Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management

GlobeNewswire June 22, 2023

Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial

GlobeNewswire June 12, 2023

Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide

GlobeNewswire June 2, 2023

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

GlobeNewswire May 25, 2023

Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

Canada NewsWire May 19, 2023

Theratechnologies Reports on its Annual Meeting of Shareholders

GlobeNewswire May 9, 2023

Theratechnologies' Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

GlobeNewswire May 4, 2023

Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies

GlobeNewswire April 18, 2023